Strategic fundraising Leverage the recent $35M Series B to identify potential strategic partners, distributors, or OEM collaborations in the medical device and aesthetics space to accelerate Brella SweatControl adoption.

Clinical validation Capitalize on the pivotal clinical study findings and pilot data to target clinics and dermatology practices focusing on hyperhidrosis treatment, offering proven efficacy evidence and patient outcomes.

Aesthetic market fit Position Brella as a complementary solution for aesthetic clinicians seeking non-invasive, rapid-treatment options for excessive underarm sweating, expanding offerings in aesthetics centers and medi-spas.

Tech and digital Utilize the existing tech stack and digital footprint (Shopify, HubSpot, Google Cloud) to optimize lead capture, nurture campaigns, and e-commerce for direct-to-practice sales and clinician education resources.

Growth enablers Target smaller to mid-sized medical device firms and dermatology networks lacking similar non-invasive hyperhidrosis solutions, leveraging funding visibility and early success data to accelerate partnerships and co-marketing opportunities.